01 Mar 2026
AMP UK Introduces Real-time Test Enabling Routine Oral Cancer Screening in General Practice
)
As a professional dental practitioner, you will already be aware of the dangers of oral cancer in your patients. Late-stage oral cancer diagnosis remains a major challenge, with over 72% of cases identified at stage III or IV and a five-year survival rate of around 50% worldwide. Yet 29% of dental patients present with an oral abnormality during routine visits. Many potentially malignant lesions look harmless in their early stages, making visual exams alone an uncertain foundation for decision-making. The BeVigilant™ OraFusion™ System, now being introduced to UK dental practices by AMP UK, provides an opportunity to approach this differently. It is the first and only real-time, biomarker-based early oral cancer screening system available, offering dentists a practical way to support earlier intervention and clearer clinical pathways.
Aesthetic Medical Partnership has introduced the BeVigilant OraFusion System, a new chairside screening tool that provides an objective indication of whether patients may require further investigation, supporting clinical decision-making directly within the appointment. The platform uses a saliva-based lateral flow immunoassay and integrated digital reader to analyse biomarker levels alongside patient clinical risk factors.
.png){kind=logo}
